Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today.
Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in the research, we are that much closer to helping millions of Americans slow the devastating effects of cognitive decline from Alzheimer’s disease. As researchers continue to develop new treatments that improve and save lives, we at GAP are equally committed to ensuring that clinical research is accelerated and inclusive, so that treatments work for everyone.
—John Dwyer, Global Alzheimer’s Platform Foundation (GAP) President
—END—
For immediate release: Contact: media@globalalzplatform.org
About GAP Foundation
The nonprofit Global Alzheimer’s Platform Foundation® (GAP) was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. GAP recently closed its Bio-Hermes study, a blood-based and digital biomarker platform study, with 24 percent representation from traditionally underrepresented communities.